HepaRegeniX GmbH

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor

HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor

HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors

HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences

HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther

HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 inhibitor HRX 0215

HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model

HepaRegeniX hires industry expert Dr. Markus Weissbach as Senior Clinical Advisor

HepaRegeniX GmbH to deliver an oral presentation of preclinical results on MKK4 inhibition in liver regeneration at The Liver Meeting(R) 2020

HepaRegeniX GmbH hires industry veteran Dr David Shapiro as Senior Medical Advisor

HepaRegeniX GmbH achieves successful proof of efficacy in acute liver disease models for selected MKK4 inhibitors

HepaRegeniX GmbH Raises EUR9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases